Cetuximab, a monoclonal antibody targeting EGFR, is one of the few drugs approved by FDA for use in HNSCC, but its response rate is only 13% when used as monotherapy [126] (Figure 3). Here, EGFR is linked to head and neck squamous cell carcinoma.